News & Trends
The Oral GLP-1 Race: What the First Pill-vs-Pill Head-to-Head Trial Actually Showed
ACHIEVE-3 pitted orforglipron against oral semaglutide and orforglipron won on A1c and weight — but it was a type 2 diabetes trial, and orforglipron had more GI side effects and twice the discontinuation rate. What that does and does not mean for weight loss.
GLP-1s Are Replacing Surgery for Teens With Obesity: What Families Should Know
A JAMA Pediatrics study of 204,000+ patients aged 13–25 finds GLP-1-only treatment rose to 96.1% while bariatric surgery fell to 3.7%. The adolescent evidence, the unknowns, and what to ask a pediatrician.
US Obesity Rate Is Falling as GLP-1 Use Hits 11%: What Gallup's Numbers Show
Gallup finds US adult obesity at 36.4% in 2026, down from a 39.9% peak, while 1 in 9 adults now take a GLP-1. What the survey shows — and what it can't.
Semaglutide and Rare Vision Loss: What the NAION Evidence Shows
A 2026 meta-analysis and Europe's 2025 label decision tie semaglutide to a very rare optic-nerve condition. The absolute risk in plain numbers, and what to do.
FDA Moves to Make the Compounded GLP-1 Ban Permanent: Comment Period Closes July 30
The FDA has proposed permanently excluding semaglutide, tirzepatide and liraglutide from large-scale compounding. The comment period, extended once, closes July 30, 2026. What's proposed vs. final — and what to do if you're on a compounded program.
The World Cup Is Over. The Walking Isn't: What a Month of Soccer Fever Says About How America Moves
Spain beat Argentina 1-0 to win the 2026 World Cup at MetLife Stadium. Here's what a month of watch parties, pickup games, and long walks to the stadium can teach us about everyday movement — and what elite-athlete routines can't.